Konecki D S, Benedum U M, Gerdes H H, Huttner W B
Cell Biology Programme, European Molecular Biology Laboratory, Heidelberg, Federal Republic of Germany.
J Biol Chem. 1987 Dec 15;262(35):17026-30.
A full-length clone encoding human chromogranin A has been isolated from a lambda gt10 cDNA library of a human pheochromocytoma. The nucleotide sequence reveals that human chromogranin A is a 439-residue protein preceded by an 18-residue signal peptide. Comparison of the protein sequence of human chromogranin A with that of bovine chromogranin A shows high conservation of the NH2-terminal and COOH-terminal domains as well as the potential dibasic cleavage sites, whereas the middle portion shows remarkable sequence variation (36%). This part of human chromogranin A contains a sequence homologous to porcine pancreastatin at residues 250-301. The sequence variation in this part of human chromogranin A compared to porcine pancreastatin is 32% and thus of the same magnitude as that between human and bovine chromogranin A. Therefore, the difference between porcine pancreastatin and the corresponding portions of bovine or human chromogranin A can be explained by species variation, suggesting that pancreastatin is derived from chromogranin A itself rather than a protein that is only similar to chromogranin A. Moreover, the pancreastatin sequence contained in human chromogranin A is flanked by sites for proteolytic processing. Together, these observations suggest that human chromogranin A may be the precursor for a human pancreastatin molecule and possibly for other, as yet unidentified, biologically active peptides.
已从人嗜铬细胞瘤的λgt10 cDNA文库中分离出编码人嗜铬粒蛋白A的全长克隆。核苷酸序列显示,人嗜铬粒蛋白A是一种由439个氨基酸残基组成的蛋白质,其前有一个18个氨基酸残基的信号肽。将人嗜铬粒蛋白A的蛋白质序列与牛嗜铬粒蛋白A的序列进行比较,结果显示其氨基末端和羧基末端结构域以及潜在的双碱性裂解位点具有高度保守性,而中间部分则表现出显著的序列差异(36%)。人嗜铬粒蛋白A的这一部分在250-301位氨基酸残基处含有一段与猪胰抑制素同源的序列。与人胰抑制素相比,人嗜铬粒蛋白A这一部分的序列差异为32%,与人和牛嗜铬粒蛋白A之间的差异程度相同。因此,猪胰抑制素与牛或人嗜铬粒蛋白A相应部分之间的差异可以用物种差异来解释,这表明胰抑制素是由嗜铬粒蛋白A本身衍生而来,而不是一种仅与嗜铬粒蛋白A相似的蛋白质。此外,人嗜铬粒蛋白A中包含的胰抑制素序列两侧是蛋白水解加工位点。综上所述,这些观察结果表明,人嗜铬粒蛋白A可能是人类胰抑制素分子以及其他尚未确定的生物活性肽的前体。